Regeneron Pharmaceuticals, Inc. company logo

# 1st Gen Model Regeneron Pharmaceuticals, Inc. Pharmaceutical preparations

57.78% successful of 90 deals
$383.12 Last close price
at 14-dec-2017


Model's trade recommendations -5.17% Return for period

-7.21% Annual return

$41.54B Market Cap

β 1.53  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period -5.17%
52wk return -2.27%
52wk Range
Sortino ratio -0.45
Sharpe ratio -0.35
Norm. RMSE 0.73%
Downside risk 13.69%
Volatility 17.89%
  • BUY Analysts consensus recommendation

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Regeneron Pharmaceuticals, Inc. (REGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for REGN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 96M
P/E 33.48
Shares Outstanding 107M
% Held by Insiders 10.80%
% Held by Institutions 66.67%
EPS (last reported FY) $8.26
EPS (last reported Q) $3.32
EPS, estimated (last reported Q) $3.79
Total revenues $5 B
Net income $1 B